SuperworthEdwards Lifesciences profit margin EW
Gross, operating and net profit as a share of revenue over the last twelve months, from 2009.
- Net margin, 12 months
- 15.4%
- Operating margin, 12 months
- 22.3%
- Net margin on a year earlier
- −57.5 pts
- Peer median
- 14.2%
Over the twelve months to Jun 30, 2026, Edwards Lifesciences kept 15.4% of its revenue as net profit, with an operating margin of 22.3% and a gross margin of 77.8%.
Five years earlier its net margin was 29.7%.
The median for 7 medical device stocks of a similar size is 14.2%.
Profit margin over time
Fiscal year by fiscal year
| Fiscal year | Net margin | Operating margin | Gross margin |
|---|---|---|---|
| FY2025 | 17.7% | 20.8% | 78.0% |
| FY2024 | 76.7% | 25.3% | 79.5% |
| FY2023 | 28.0% | 28.3% | 80.5% |
| FY2022 | 28.3% | 32.5% | 79.9% |
| FY2021 | 28.7% | 32.3% | 76.1% |
| FY2020 | 18.8% | 20.5% | 75.4% |
| FY2019 | 24.1% | 26.4% | 74.4% |
| FY2018 | 19.4% | 20.1% | 74.8% |
| FY2017 | 17.0% | 31.7% | 74.5% |
| FY2016 | 19.2% | 25.3% | 73.1% |
| FY2015 | 19.8% | 25.5% | 75.2% |
| FY2014 | 34.9% | 50.0% | 73.1% |
| FY2013 | 19.0% | 25.3% | 74.7% |
| FY2012 | 15.4% | 20.7% | 74.0% |
| FY2011 | 14.1% | 16.6% | 70.8% |
Quarter by quarter
| Quarter | Ended | Net margin, 12 months | Change on a year | Operating margin |
|---|---|---|---|---|
| Q2 FY26 | 15.4% | −57.5 pts | 22.3% | |
| Q1 FY26 | 17.4% | −58.3 pts | 21.4% | |
| Q4 FY25 | 17.7% | −59.1 pts | 20.8% | |
| Q3 FY25 | 23.2% | −54.9 pts | 24.2% | |
| Q2 FY25 | 73.0% | +44.7 pts | 25.8% | |
| Q1 FY25 | 75.7% | +48.1 pts | 25.8% | |
| Q4 FY24 | 76.7% | +48.8 pts | 25.3% | |
| Q3 FY24 | 78.2% | +50.1 pts | 27.6% | |
| Q2 FY24 | 28.3% | +1.4 pts | 28.4% | |
| Q1 FY24 | 27.6% | −0.7 pts | 26.9% | |
| Q4 FY23 | 28.0% | −0.3 pts | 28.3% | |
| Q3 FY23 | 28.1% | +0.9 pts | 28.8% |
Against its peers
Companies in Medical - Devices nearest Edwards Lifesciences' size, closest first, today.
| Company | Profit margin |
|---|---|
| EWEdwards Lifesciences | 15.4% |
| BSXBoston Scientific | 17.5% |
| GEHCGE HealthCare Technologies | 9.3% |
| DXCMDexCom | 20.1% |
| SYKStryker | 14.4% |
| MDTMedtronic | 13.9% |
| ZBHZimmer Biomet | 9.5% |
| ABTAbbott Laboratories | n/m |
| Peer median | 14.2% |
Where Edwards Lifesciences ranks
What the profit margin tells you
Profit as a share of revenue at three levels: gross (after making the product), operating (after running the business) and net (after everything, including tax and interest).
Compare within an industry. 10% is superb for a retailer and poor for a software company.
More on Edwards Lifesciences
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.